One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome

被引:63
作者
Santamaria, A. [1 ]
Giordano, D. [2 ]
Corrado, F. [1 ]
Pintaudi, B. [3 ]
Interdonato, M. L. [1 ]
Di Vieste, G. [3 ]
Di Benedetto, A. [3 ]
D'Anna, R. [1 ]
机构
[1] Univ Messina, Dept Obstet & Gynecol Sci, I-98100 Messina, Italy
[2] Policlin Hosp, Reggio Di Calabria, Italy
[3] Univ Messina, Dept Internal Med, I-98100 Messina, Italy
关键词
METABOLIC SYNDROME; POSTMENOPAUSE; MYO-INOSITOL; HOMA-IR; POLYCYSTIC-OVARY-SYNDROME; CORONARY-HEART-DISEASE; D-CHIRO-INOSITOL; CARDIOVASCULAR-DISEASE; INSULIN ACTION; RISK; HYPERINSULINEMIA; CHOLESTEROL; MEN;
D O I
10.3109/13697137.2011.631063
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To evaluate the 12-month effect of myo-inositol treatment on some biochemical parameters of women affected by metabolic syndrome. Methods Eighty outpatient postmenopausal women, affected by metabolic syndrome, were enrolled in a 12-month study. All women were treated with a low-energy diet, and then they were randomly assigned to myo-inositol 2 g b.i.d. (n = 40) or placebo (n = 40). All the women were evaluated for serum glucose, insulin, HOMA-IR (Homeostasis Model Assessment-Insulin Resistance), triglycerides, total and high density lipoprotein cholesterol, body mass index (BMI), waist circumference and blood pressure at baseline and after 12 months of treatment. Results With the exception of BMI and waist circumference, after 12 months of treatment, all the parameters studied showed a significant improvement in the myo-inositol group compared to the control group. At the end of the study, in the myo-inositol group, the number of women without metabolic syndrome was eight (20%) whereas, in the control group, only one woman no longer had the metabolic syndrome after 12 months of diet. Conclusions Myo-inositol might be considered one of the insulin-sensitizing substances in the treatment of metabolic syndrome
引用
收藏
页码:490 / 495
页数:6
相关论文
共 17 条
[1]   High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: A systematic review [J].
Amarenco, Pierre ;
Labreuche, Julien ;
Touboul, Pierre-Jean .
ATHEROSCLEROSIS, 2008, 196 (02) :489-496
[2]  
[Anonymous], 2001, JAMA, V285, P2486
[3]   Uncoupling Between Insulin and Release of a D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator of Insulin Action in Obese Women With Polycystic Ovary Syndrome [J].
Baillargeon, Jean-Patrice ;
Iuorno, Maria J. ;
Apridonidze, Teimuraz ;
Nestler, John E. .
METABOLIC SYNDROME AND RELATED DISORDERS, 2010, 8 (02) :127-135
[4]  
De Micheli A, 2008, ACTA DIABETOL
[5]   Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome [J].
Esposito, K ;
Ciotola, M ;
Carleo, D ;
Schisano, B ;
Saccomanno, F ;
Sasso, FC ;
Cozzolino, D ;
Assaloni, R ;
Merante, D ;
Ceriello, A ;
Giugliano, D .
DIABETES CARE, 2006, 29 (05) :1071-1076
[6]   HYPERINSULINEMIA DOES NOT INCREASE THE RISK OF FATAL CARDIOVASCULAR-DISEASE IN ELDERLY MEN OR WOMEN WITHOUT DIABETES - THE RANCHO-BERNARDO STUDY, 1984-1991 [J].
FERRARA, A ;
BARRETTCONNOR, EL ;
EDELSTEIN, SL .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 140 (10) :857-869
[7]   Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: A post-hoc analysis of the BIGPRO1 trial [J].
Fontbonne, A. ;
Diouf, I. ;
Baccara-Dinet, M. ;
Eschwege, E. ;
Charles, M-A. .
DIABETES & METABOLISM, 2009, 35 (05) :385-391
[8]   Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome [J].
Genazzani, Alessandro D. ;
Lanzoni, Chiara ;
Ricchieri, Federica ;
Jasonni, Valerio M. .
GYNECOLOGICAL ENDOCRINOLOGY, 2008, 24 (03) :139-144
[9]   Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study [J].
Giordano, Domenico ;
Corrado, Francesco ;
Santamaria, Angelo ;
Quattrone, Simona ;
Pintaudi, Basilio ;
Di Benedetto, Antonino ;
D'Anna, Rosario .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2011, 18 (01) :102-104
[10]   Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome [J].
Gupta, A. K. ;
Smith, S. R. ;
Greenway, F. L. ;
Bray, G. A. .
DIABETES OBESITY & METABOLISM, 2009, 11 (04) :330-337